{"id":"NCT04112303","sponsor":"Gilead Sciences","briefTitle":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis","officialTitle":"A Phase 3 Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic HCV Infection and Compensated Cirrhosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-16","primaryCompletion":"2021-03-26","completion":"2021-06-25","firstPosted":"2019-10-02","resultsPosted":"2022-04-20","lastUpdate":"2022-04-20"},"enrollment":37,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"SOF/VEL","otherNames":["GS-7977/5816","EpclusaÂ®"]}],"arms":[{"label":"SOF/VEL","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in adults with chronic hepatitis C virus (HCV) infection and compensated cirrhosis.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) < Lower Limit of Quantification (LLOQ) 12 Weeks After Discontinuation of Treatment (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL","deltaMin":100,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":22,"countries":["Japan"]},"refs":{"pmids":["35802063"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":37},"commonTop":["Headache","Diarrhoea"]}}